{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:23:54Z","timestamp":1792106634381,"version":"4.4.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Synchronous systemic and de novo secondary central nervous system (CNS) large B-cell lymphoma (LBCL) is an aggressive clinical entity with a historically poor prognosis. Given the rarity of this presentation, prospective studies are limited, and treatment paradigms and outcomes are extrapolated from small, heterogenous retrospective studies. We performed a retrospective study with extended follow-up for 63 consecutive patients with previously untreated synchronous systemic and de novo secondary CNS LBCLs presenting to 2 institutions over 21 years. Most patients had diffuse LBCL (73%) and were treated with an average of 6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) intercalated with high-dose IV methotrexate (R-CHOP-M). The overall response rate was 84% (75% complete). With a median follow-up of 8.1 years, the median progression-free survival (PFS) was 1.2 years, and the 6-year PFS rate was 37%. The median overall survival (OS) was 7.9 years, and the 6-year OS rate was 52%. Normal lactate dehydrogenase (LDH), low International Prognostic Index (IPI) score, and brain parenchymal-only CNS disease were associated with improved PFS, whereas normal LDH and parenchymal disease were associated with OS. The 25% of patients who underwent consolidation with high-dose chemotherapy (HDC) and autologous stem cell transplant (ASCT) had superior PFS and OS than patients who did not receive a transplant, with particular benefit in those with IPI score of \u22653. This study demonstrates that a proportion of patients presenting with secondary CNS involvement are cured with upfront chemoimmunotherapy with or without HDC\/ASCT and helps identify prognostically favorable subgroups, which can guide counseling of patients with this rare, high-risk clinical presentation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017127","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T12:22:41Z","timestamp":1761913361000},"page":"479-491","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2463-0560","authenticated-orcid":false,"given":"J. Erika","family":"Haydu","sequence":"first","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":false,"given":"Robert A.","family":"Redd","sequence":"additional","affiliation":[{"name":"3Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-6065","authenticated-orcid":false,"given":"Matthew M.","family":"Lei","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim P.","family":"Hochberg","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-1909","authenticated-orcid":false,"given":"Jeffrey A.","family":"Barnes","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3062-6819","authenticated-orcid":false,"given":"Jacob D.","family":"Soumerai","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April F.","family":"Eichler","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-817X","authenticated-orcid":false,"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-0176","authenticated-orcid":false,"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Arrillaga-Romany","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-1841","authenticated-orcid":false,"given":"J. R.","family":"McFaline-Figueroa","sequence":"additional","affiliation":[{"name":"5Department of Neurology and Medicine, New York University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-6419","authenticated-orcid":false,"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Takvorian","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugonma N.","family":"Chukwueke","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-5129","authenticated-orcid":false,"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3943-6608","authenticated-orcid":false,"given":"P. Connor","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5310","authenticated-orcid":false,"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"6Department of Neurosurgery, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-0136","authenticated-orcid":false,"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nayak","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"},{"name":"4Department of Lymphoma, Dana-Farber Brigham Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma, Mass General Cancer Center, Boston, MA"},{"name":"2Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"5","key":"2026012709365742400_bib1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026012709365742400_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"19","key":"2026012709365742400_bib3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012709365742400_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2026012709365742400_bib5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2026012709365742400_bib6","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2026012709365742400_bib7","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026012709365742400_bib8","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"9880","key":"2026012709365742400_bib9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"2026012709365742400_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"2026012709365742400_bib11","doi-asserted-by":"crossref","first-page":"113436","DOI":"10.1016\/j.ejca.2023.113436","article-title":"A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma","volume":"196","author":"Habringer","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"2026012709365742400_bib12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.31557\/APJCP.2023.24.2.623","article-title":"The outcomes of diffuse large B-cell lymphoma patients with synchronous and early central nervous system involvement: a single-center experience","volume":"24","author":"Al-Mansour","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"2026012709365742400_bib13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14267","article-title":"Dose-adjusted EPOCH-R and mid-cycle high dose methotrexate for patients with systemic lymphoma and secondary CNS involvement","volume":"179","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"2026012709365742400_bib14","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3324\/haematol.2015.126110","article-title":"Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network","volume":"100","author":"Damaj","year":"2015","journal-title":"Haematologica"},{"issue":"2","key":"2026012709365742400_bib15","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026012709365742400_bib16","doi-asserted-by":"crossref","first-page":"20406207221112900","DOI":"10.1177\/20406207221112900","article-title":"Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study","volume":"13","author":"Fleming","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"2026012709365742400_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1285026","article-title":"Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma","volume":"58","author":"Nijland","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2026012709365742400_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.25558","article-title":"Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: a retrospective multicenter study","volume":"94","author":"Perry","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2026012709365742400_bib19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clml.2017.08.100","article-title":"High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement","volume":"17","author":"Qualls","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7-8","key":"2026012709365742400_bib20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000517531","article-title":"Outcome of a real-world patient cohort with secondary CNS lymphoma treated with high-intensity chemoimmunotherapy and autologous stem cell transplantation","volume":"44","author":"Thiele","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"2","key":"2026012709365742400_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.16064","article-title":"Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance","volume":"187","author":"Wight","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"2026012709365742400_bib22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clml.2020.02.009","article-title":"Durable survival outcomes in primary and secondary central nervous system lymphoma after high-dose chemotherapy and autologous stem cell transplantation using a thiotepa, busulfan, and cyclophosphamide conditioning regimen","volume":"20","author":"Young","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"2026012709365742400_bib23","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2026012709365742400_bib24","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1200\/JCO.2021.39.15_suppl.7506","article-title":"Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: results of CALGB 51101 (Alliance)","volume":"39","author":"Batchelor","year":"2021","journal-title":"J Clin Oncol"},{"issue":"31","key":"2026012709365742400_bib25","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2026012709365742400_bib26","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","article-title":"Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)","volume":"38","author":"Omuro","year":"2020","journal-title":"J Clin Oncol"},{"issue":"30","key":"2026012709365742400_bib27","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026012709365742400_bib28","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"7","key":"2026012709365742400_bib29","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2026012709365742400_bib30","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026012709365742400_bib31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026012709365742400_bib32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026012709365742400_bib33","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"issue":"33","key":"2026012709365742400_bib34","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026012709365742400_bib35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"26","key":"2026012709365742400_bib36","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026012709365742400_bib37","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2026012709365742400_bib38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2026012709365742400_bib39","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10254","key":"2026012709365742400_bib40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2026012709365742400_bib41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026012709365742400_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026012709365742400_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (axi-cel) in patients with secondary CNS involvement: results from the US Lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026012709365742400_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","volume":"16","author":"Epperla","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2026012709365742400_bib45","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2026012709365742400_bib46","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","article-title":"Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"issue":"20","key":"2026012709365742400_bib47","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2026012709365742400_bib48","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/ajh.27505","article-title":"Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosis","volume":"99","author":"Kaulen","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"2026012709365742400_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"2026012709365742400_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"13","key":"2026012709365742400_bib51","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2026012709365742400_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026012709365742400_bib53","first-page":"3013","article-title":"Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance","volume":"109","author":"Wight","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/479\/2498509\/blooda_adv-2025-017127-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/2\/479\/2498509\/blooda_adv-2025-017127-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:37:10Z","timestamp":1769524630000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/2\/479\/547995\/A-retrospective-study-of-treatment-and-outcomes-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017127","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,27]]},"published":{"date-parts":[[2026,1,16]]}}}